SYShu-Li Yang

Shu-Li Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shu-Li Yang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Chun-Lin Pan

    Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100026, China

    1 shared publication
  • Haili Kang

    Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital

    1 shared publication
  • Haiyun Yu

    Department of Pathology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital

    1 shared publication
  • Jiandong Wang

    Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100026, China

    1 shared publication
  • Jiao Wang

    Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital

    1 shared publication
  • Kai-Bing Qu

    Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100026, China

    1 shared publication

Latest Publications

  • Open Access

    Case Report: SMARCA4-deficient uterine sarcoma with exceptional response to immune checkpoint inhibitor therapy

    by Qun Liu, Haili Kang, Jiao Wang, Haiyun Yu, Shuli Yang

    Background: SMARCA4-deficient uterine sarcoma (SDUS) is a rare and aggressive undifferentiated uterine mesenchymal malignancy characterized by inactivation of SMARCA4 gene leading to loss of nuclear SMARCA4/BRG1 immunohistochemical staining. Fewer than 40 cases have been reported worldwide since its first description in 2018, and the disease carries a median overall survival of only 7–9 months. SMARCA4 loss is observed across a spectrum of aggressive neoplasms, including smallcell carcinoma of the ovary, hypercalcemic type (SCCOHT), SMARCA4-deficient thoracic sarcoma, and SMARCA4-deficient nonsmallcell lung cancer, suggesting shared therapeutic vulnerabilities. Case: A 48-year-old woman presented with irregular vaginal bleeding for two years. Physical examination and magnetic resonance imaging (MRI) revealed a large pelvic mass centered in the uterus. The patient underwent total abdominal hysterectomy with bilateral salpingectomy, and pathological examination confirmed SDUS (stage IB, FIGO 2018). Genetic testing identified a somatic SMARCA4 splice-site variant (c.3951 + 2T>G). The tumor was TMB-low (0.06 Mut/Mb), PD-L1-negative (<1% by 22C3 pharmDx), microsatellite stable (MSS), and HLA-class-I heterozygous. Despite these conventional immunotherapy-unfavorable markers, adjuvant Gemcitabine-Docetaxel chemotherapy combined with pembrolizumab yielded a progression-free survival (PFS) of 23 months as of the last follow-up, far exceeding the previously reported median survival of SDUS. Conclusion: This case demonstrates that immune checkpoint inhibitors (ICI) may provide meaningful therapeutic benefit in selected patients with SDUS, including those lacking conventional predictive biomarkers (TMB-high, PD-L1 positivity, or MSI-H). While the observed 23-month PFS supports the hypothesis that SMARCA4 deficiency merits further investigation as a candidate molecular correlate of ICI responsiveness, definitive validation requires larger cohorts and ideally prospective, biomarker-driven studies. Definitive diagnosis relies on morphologic evaluation, loss of BRG1 protein expression by immunohistochemistry with retained INI-1, and detection of SMARCA4 gene alterations through genetic testing.

  • Open Access

    Mechanism-Driven Evolution of Fertility-Sparing Treatment and Precision Management of Special Populations in Endometrial Cancer: A Review

    by Kai-Bing Qu, Chun-Lin Pan, Ming-Yue Zhang, Zhuo-Ying Du, Sheng-Qian Wang, Shu-Li Yang, Yu-Mei Wu, Jian-Dong Wang, Yue He

    Endometrial cancer is increasingly diagnosed in patients who have not yet completed childbearing. For carefully selected patients with grade 1 endometrioid endometrial carcinoma confined to the endometrium, fertility-sparing treatment (FST) can preserve reproductive potential but requires rigorous histologic surveillance. In eligible patients, oral progestins and/or the levonorgestrel-releasing intrauterine system (LNG-IUS) remain the mainstay of fertility-sparing treatment, with hysteroscopic lesion resection incorporated in selected cases. Obesity, polycystic ovary syndrome, abnormalities in glucose metabolism, molecular subtype, and primary or acquired progestin resistance collectively contribute to heterogeneity in treatment response and the risk of recurrence. This narrative review critically integrates current guidelines, randomized controlled trials, prospective studies, retrospective cohorts, and early exploratory evidence to evaluate the biological rationale, clinical positioning, efficacy, safety, and maturity of evidence for progestin-based therapy, metabolic interventions, combined endocrine approaches, molecularly guided strategies, and exploratory immunotherapeutic approaches. We further propose an integrated clinical pathway encompassing candidate selection, molecular assessment, response evaluation, transition to pregnancy, retreatment after recurrence, and timely conversion to definitive surgery. Importantly, this review distinguishes guideline-supported approaches from adjunctive, investigational, and exploratory strategies. Major evidence gaps include inconsistent definitions of treatment response, limited prospective molecularly stratified data, uncertain reproductive safety of emerging systemic therapies, and insufficient long-term data on pregnancy outcomes and offspring.